Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GNG2 | P59768 | 1/20 | 0.41 |
| ▸ | GNB1 | P62873 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13862071 | 0.85 | FFAR4 (0.50) | NPC1RAB9AFADS1KMT2AMEN1 | |
| SCHEMBL30739972 | 0.83 | HDAC1 (0.56) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL1240998 | 0.83 | HDAC1 (0.56) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL2092311 | 0.82 | RAB9A (0.65) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL27474740 | 0.81 | NPC1 (0.73) | NPC1RAB9AFADS1KMT2AMEN1 | |
| SCHEMBL8361373 | 0.80 | CYP1A2 (0.51) | FADS1GAASMN1; SMN2HDAC1MAPT | |
| SCHEMBL2310611 | 0.80 | SMN1; SMN2 (0.50) | NPC1RAB9AFADS1KMT2AMEN1 | |
| SCHEMBL8230228 | 0.79 | TSHR (0.46) | NPC1RAB9AFADS1KMT2AMEN1 | |
| SCHEMBL7914590 | 0.79 | L3MBTL1 (0.58) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL9995242 | 0.79 | TGM2 (0.59) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045829-B1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER CROPSCIENCE AG (DE) | 2003-06-04 | — | — | EP | claimed |
| US-6218565-B1 | 1-FLUORO-2,4-DIAMINO-BENZENE IS REACTED WITH SULPHONYL CHLORIDES, CARBONYL CHLORIDES OR CHLORORFORMIC ESTERS IN THE PRESENCE OF AN ACID ACCEPTOR AND IN THE PRESENCE OF A DILUENT | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | claimed |
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2024-02-15 | — | — | US | disclosed |
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| EP-3036231-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | JUBILANT BIOSYS LIMITED (IN) | 2019-04-30 | — | — | US | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-6218565-B1 | 1-FLUORO-2,4-DIAMINO-BENZENE IS REACTED WITH SULPHONYL CHLORIDES, CARBONYL CHLORIDES OR CHLORORFORMIC ESTERS IN THE PRESENCE OF AN ACID ACCEPTOR AND IN THE PRESENCE OF A DILUENT | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| US-6218565-B1 | 1-FLUORO-2,4-DIAMINO-BENZENE IS REACTED WITH SULPHONYL CHLORIDES, CARBONYL CHLORIDES OR CHLORORFORMIC ESTERS IN THE PRESENCE OF AN ACID ACCEPTOR AND IN THE PRESENCE OF A DILUENT | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| US-6218565-B1 | 1-FLUORO-2,4-DIAMINO-BENZENE IS REACTED WITH SULPHONYL CHLORIDES, CARBONYL CHLORIDES OR CHLORORFORMIC ESTERS IN THE PRESENCE OF AN ACID ACCEPTOR AND IN THE PRESENCE OF A DILUENT | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| CN-1285816-A | Method for producing N-(3-amino-4-fluorophenyl)-sulphonamides, N-(3-amino-4-fluorophenyl) carboxylic acid amides and N-(3-amino-4-fluorophenyl) carbamates | BAYER AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| CN-1285816-A | Method for producing N-(3-amino-4-fluorophenyl)-sulphonamides, N-(3-amino-4-fluorophenyl) carboxylic acid amides and N-(3-amino-4-fluorophenyl) carbamates | BAYER AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| EP-1045829-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AG (DE) | 2000-10-25 | — | — | EP | disclosed |
| EP-1045829-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AG (DE) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035122-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035122-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | NPC1 1707/4885RAB9A 2690/4885FADS1 2192/4885 |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | TYMP, EGFR, TK1 | NPC1 2162/4885RAB9A 2595/4885FADS1 3052/4885 |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885FADS1 1551/4885 |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | TYMP, EGFR, TK1 | NPC1 2162/4885RAB9A 2595/4885FADS1 3052/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885FADS1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.